Evidence map›Paper›PMID 40591411›Full record

ArticleThe Journal of clinical investigation2025

The human glucocorticoid receptor variant rs6190 increases blood cholesterol and promotes atherosclerosis.

Hima Bindu Durumutla, April Haller, Greta Noble, Ashok Daniel Prabakaran, Kevin McFarland, Hannah Latimer, Akanksha Rajput, Olukunle Akinborewa, Bahram Namjou-Khales, David Y Hui and 1 more

Abstract read
In one paragraph

Article in The Journal of clinical investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Hima Bindu DurumutlaMolecular Cardiovascular Biology, Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
April HallerDepartment of Pathology, and.
Greta NobleMolecular Cardiovascular Biology, Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Ashok Daniel PrabakaranMolecular Cardiovascular Biology, Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Kevin McFarlandMolecular Cardiovascular Biology, Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Hannah LatimerMolecular Cardiovascular Biology, Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Akanksha RajputMolecular Cardiovascular Biology, Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Olukunle AkinborewaMolecular Cardiovascular Biology, Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Bahram Namjou-KhalesDepartment of Pediatrics.
David Y HuiDepartment of Pathology, and.
Mattia QuattrocelliMolecular Cardiovascular Biology, Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.

Funding

Polymorphic ApoE at the crossroad of lipid metabolism and inflammation in atherosclerosisR01HL156954 · NHLBI · UNIVERSITY OF CINCINNATI · PI HUI, DAVID YIU-KWAN · 2022 to 2025
$2.4M
Coordinated mechanisms to rescue bioenergetics and sarcopenia in agingR01AG078174 · NIA · CINCINNATI CHILDRENS HOSP MED CTR · PI QUATTROCELLI, MATTIA · 2022 to 2025
$1.3M
Harnessing novel glucocorticoid biology to treat diabetic cardiomyopathyR01HL166356 · NHLBI · CINCINNATI CHILDRENS HOSP MED CTR · PI QUATTROCELLI, MATTIA · 2023 to 2025
$1.2M
CHRONO-MECHANISMS of CARDIOMETABOLIC PHARMACOLOGYR56HL158531 · NHLBI · CINCINNATI CHILDRENS HOSP MED CTR · PI QUATTROCELLI, MATTIA · 2021 to 2021
$398k
ROLE OF CIRCADIAN RHYTHM AND INTERMITTENT DOSING IN MUSCLE TRIGLYCERIDE LIPASE INDUCTION BY GLUCOCORTICOIDSR03DK130908 · NIDDK · CINCINNATI CHILDRENS HOSP MED CTR · PI QUATTROCELLI, MATTIA · 2022 to 2023
$249k
NHLBI NIH HHS R01 HL156954NHLBI NIH HHS R01 HL166356NHLBI NIH HHS R56 HL158531NIA NIH HHS R01 AG078174NIDDK NIH HHS R03 DK130908
6 · The paper itself

Abstract

Elevated cholesterol poses cardiovascular risks. The glucocorticoid receptor (GR) harbors a still undefined role in cholesterol regulation. Here, we report that a coding SNP in the gene encoding the GR, rs6190, is associated with increased cholesterol in women according to UK Biobank and All of Us (NIH) datasets. In SNP-genocopying mice, we found that the SNP enhanced hepatic GR activity to transactivate Pcsk9 and Bhlhe40, negative regulators of LDL and HDL receptors, respectively. In mice, the SNP was sufficient to elevate circulating cholesterol across all lipoprotein fractions and the risk and severity of atherosclerotic lesions on the proatherogenic hAPOE*2/*2 background. The SNP effect on atherosclerosis was blocked by in vivo liver knockdown of Pcsk9 and Bhlhe40. Also, corticosterone and testosterone were protective against the mutant GR program in cholesterol and atherosclerosis in male mice, while the SNP effect was additive to estrogen loss in females. Remarkably, we found that the mutant GR program was conserved in human hepatocyte-like cells using CRISPR-engineered, SNP-genocopying human induced pluripotent stem cells. Taken together, our study leverages a nonrare human variant to uncover a GR-dependent mechanism contributing to atherogenic risk, particularly in women.

Indexed as

AtherosclerosisCholesterolPolymorphism, Single NucleotideReceptors, GlucocorticoidAnimalsFemaleHumansMaleMiceProprotein Convertase 9CholesterolPCSK9 protein, humanPcsk9 protein, mouseProprotein Convertase 9Receptors, GlucocorticoidAtherosclerosisCholesterolEndocrinologyEpigeneticsGeneticsMetabolism

Identifiers

PMID40591411
PMCPMC12404749

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.